GemOx-R regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of xxx used to treat xxx. ==Regimen== {{chemo|x|xx}} {{chemo|x|xx}}..." |
No edit summary |
||
| Line 2: | Line 2: | ||
{{SI}} | {{SI}} | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of | {{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[gemcitabine]] and [[oxaliplatin]] used to treat refractory and relapsing [[mantle cell lymphoma]].<ref name="pmid17990179">{{cite journal| author=Rodríguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcón J et al.| title=Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. | journal=Leuk Lymphoma | year= 2007 | volume= 48 | issue= 11 | pages= 2172-8 | pmid=17990179 | doi=10.1080/10428190701618268 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17990179 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo| | {{chemo|Gem|Gemcitabine}} | ||
{{chemo| | {{chemo|Ox|Oxaliplatin}} | ||
{{chemo| | {{chemo|R|Rituximab}} | ||
==Indications== | ==Indications== | ||
*Refractory and relapsing [[mantle cell lymphoma]].<ref name="pmid17990179">{{cite journal| author=Rodríguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcón J et al.| title=Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. | journal=Leuk Lymphoma | year= 2007 | volume= 48 | issue= 11 | pages= 2172-8 | pmid=17990179 | doi=10.1080/10428190701618268 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17990179 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 19:32, 26 March 2015
|
WikiDoc Resources for GemOx-R regimen |
|
Articles |
|---|
|
Most recent articles on GemOx-R regimen Most cited articles on GemOx-R regimen |
|
Media |
|
Powerpoint slides on GemOx-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on GemOx-R regimen at Clinical Trials.gov Trial results on GemOx-R regimen Clinical Trials on GemOx-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on GemOx-R regimen NICE Guidance on GemOx-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on GemOx-R regimen Discussion groups on GemOx-R regimen Patient Handouts on GemOx-R regimen Directions to Hospitals Treating GemOx-R regimen Risk calculators and risk factors for GemOx-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for GemOx-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
GemOx-R regimen refers to a regimen consisting of rituximab, gemcitabine and oxaliplatin used to treat refractory and relapsing mantle cell lymphoma.[1]
Regimen
GemGemcitabine
OxOxaliplatin
RRituximab
Indications
- Refractory and relapsing mantle cell lymphoma.[1]
References
- ↑ 1.0 1.1 Rodríguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcón J; et al. (2007). "Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma". Leuk Lymphoma. 48 (11): 2172–8. doi:10.1080/10428190701618268. PMID 17990179.